Interleukin 1 (IL-1), IL-6, and tumour necrosis factor (TNF) a are pleiotropic cytokines produced predominantly by macrophages which have been implicated in the pathogenesis of rheumatoid arthritis (RA). Sulphasalazine has been shown to have disease modifying properties and to inhibit the production of cytokines in vitro. To evaluate the effect of sulphasalazine on cytokine production in vivo, serum cytokine levels were measured in a group of patients with RA entered into a randomised controlled trial. Serum levels of IL-la, IL-1,B, IL-6, and TNF a were measured at baseline and at two monthly intervals for six months in 17 patients receiving sulphasalazine and in 22 patients treated with placebo. The two groups of patients had a similar age and sex distribution, had had RA for less than a year, had no joint erosions, and had not been treated previously with any other disease modifying drugs.
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In the 39 patients studied IL-la was detected (>0.1 ng/ml) at baseline in 14 patients (median 0-24 ng/ml), IL-1,B in 25 patients (median 1-0 ng/ml), TNF a in 27 patients (median 1.2 ng/ml), and IL-6 in 33 patients (median 0.44 ng/ml). In the group treated with sulphasalazine there was a progressive and signficant decline in senrm IL-la, IL-1,B, and TNF a levels over the six month period (median levels at six months were <0-1, 0-12, and 0.44 ng/ml respectively). Interleukin 6 levels were significantly reduced only at the four month time point (median level of 0-23 ng/ml). These reductions were associated with improvements in clinical and laboratory measures of disease activity. In contrast patients receiving the placebo showed no changes in serum cytokine levels and no improvement in clinical and laboratory indices of disease activity. These results suggest that sulphalazne may exert its disease modifying effect partly by suppressing cytokine production in vivo. Cytokines have been implicated as important mediators of inflammation and joint destruction in rheumatoid arthritis (RA).' The development of sensitive immunoassays for cytokines has made it possible to show increased levels of some cytokines in the blood ofpatients with RA. More importantly increased levels of interleukin 1f (IL-it3)2A and tumour necrosis factor a (TNF a) 6 have been associated with disease severity in patients with RA. Although circulating IL-6 has been detected in many patients with arthritis7 8 the levels in patients with RA and patients with other inflammatory arthritides were not significantly higher than in patients with non-inflammatory arthritis.9 ' Circulating levels of IL-la in patients with RA were found to be low and not significantly different from normal control subjects. 4 Months from baseline Circulating cytokine lvels in arthritis index and the activities of daily living score there were no improvements in any of the laboratory parameters. In fact changes in the erythrocyte sedimentation rate and serum hyaluronic acid levels indicate the continuing progression of disease.20 In contrast patients receiving sulphasalazine showed improvements in all clinical and laboratory parameters. Stable levels of serum hyaluronic acid indicate control of disease progression. Therefore changes in serum cytokine levels in patients receiving sulphasalazine are clearly associated with clinical improvement.
Discussion
We have shown that successful treatment with the disease modifying drug sulphasalazine is associated with reductions in serum levels of IL-la, IL-1(3, and TNF a if these cytokines are present in detectable amounts before treatment. At least one of these three cytokines was detected in most patients (36/39). Although IL-6 was detected in the serum of most patients with RA (33/39), it was unaffected by treatment with sulphasalazine. This is consistent with our observations on the effects of sulphasalazine on cytokine production in vitro where we found that much higher concentrations of sulphasalazine (50 jig/ml) were required to inhibit IL-6 production compared. with IL-1 or TNF a production (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) [ig/ml) ( 24 In this study there was a significant decrease in the standard clinical and laboratory parameters of disease activity in those patients receiving Sap-en tabs whereas those patients receiving placebo showed no such reduction. Sulphasalazine has been shown to be beneficial in the treatment of RA25-27 (Australian Multicentre Trial Group, unpublished results) and of ankylosing spondylitis.28 29 In a comparative study sulphasaladine significantly slowed the rate of bone erosion in patients with RA compared with hydroxychloroquine.0 Like all disease modifying drugs, sulphasalazine has a spectrum of adverse reactions including rashes and gastrointestinal events. It is, however, well tolerated by patients compared with similar drugs.31 32 This study shows that sulphasalazine may inhibit cytokine production in vivo, though we do not know if this is a primary effect of the drug in vivo or a change secondary to the suppresion of inflammation. Cytokine levels were significantly reduced after two to four months of treatment with sulphasalazine. Disease activity, however, was not assessed until after four and six months when there were significant improvements in the clinical and laboratory measures (data presented only for six months). Therefore it was not possible to determine whether the changes in serum cytokine levels preceded clinical improvement. Our in vitro studies suggest that sulphasalazine may inhibit cytokine production as a primary mode of action of the drug (Danis V A et al, unpublished results). Moreover the minimal effect of sulphasalazine treatment on circulating IL-6 levels is also consistent with the in vitro data (Danis V A et al, unpublished data). There is preliminary evidence to suggest that IL-6 may have a protective and anabolic role in connective tissues-for example, by stimulating chondrocyte growth, the production of transforming growth factor (3, and the tissue inhibitor of metalloproteinases by chondrocytes (P-A Guerne et al, unpublished results). Interleukin 6 may have a protective role in arthritis and it may not be desirable to suppress its production with disease modifying drugs. Suppression of the production of potentially pathogenetic cytokines (IL-1 and TNF a) may be one mechanism of the disease modifying action of sulphasalazine in patients with RA. 
